Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Stake Increased by One Capital Management LLC

One Capital Management LLC increased its stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 31.9% in the second quarter, Holdings Channel reports. The institutional investor owned 25,402 shares of the company’s stock after acquiring an additional 6,137 shares during the quarter. One Capital Management LLC’s holdings in Invesco Biotechnology & Genome ETF were worth $1,646,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC bought a new stake in Invesco Biotechnology & Genome ETF during the second quarter valued at $26,000. GPS Wealth Strategies Group LLC bought a new stake in Invesco Biotechnology & Genome ETF during the second quarter valued at $30,000. UMB Bank n.a. bought a new stake in Invesco Biotechnology & Genome ETF during the second quarter valued at $31,000. Covestor Ltd increased its stake in Invesco Biotechnology & Genome ETF by 24.2% during the first quarter. Covestor Ltd now owns 955 shares of the company’s stock valued at $62,000 after purchasing an additional 186 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. bought a new stake in Invesco Biotechnology & Genome ETF during the first quarter valued at $232,000.

Invesco Biotechnology & Genome ETF Price Performance

PBE stock opened at $71.22 on Tuesday. Invesco Biotechnology & Genome ETF has a 1-year low of $52.47 and a 1-year high of $72.72. The firm has a fifty day moving average price of $69.53 and a two-hundred day moving average price of $65.86. The firm has a market cap of $287.73 million, a price-to-earnings ratio of 17.12 and a beta of 0.88.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.